ADMA injures the glomerular filtration barrier

Role of nitric oxide and superoxide

Mukut Sharma, Zongmin Zhou, Hiroto Miura, Andreas Papapetropoulos, Ellen T. McCarthy, Ram Sharma, Virginia J. Savin, Elias A. Lianos

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) is associated with decreased renal nitric oxide (NO) production and increased plasma levels of methylarginines. The naturally occurring guanidino-methylated arginines N-monomethyl-L-arginine (L-NMMA) and asymmetric dimethyl-L-arginine (ADMA) inhibit NO synthase activity. We hypothesized that ADMA and L-NMMA compromise the integrity of the glomerular filtration barrier via NO depletion. We studied the effect of ADMA on albumin permeability (P alb ) in isolated glomeruli and examined whether this effect involves NO- and superoxide (O 2 •- )-dependent mechanisms. ADMA at concentrations found in circulation of patients with CKD decreased cGMP and increased P alb in a dose-dependent manner. A similar increase in P alb was caused by L-NMMA but at a concentration two orders of magnitude higher than that of ADMA. NO donor DETA-NONOate or cGMP analog abrogated the effect of ADMA on P alb . The SOD mimetic tempol or the NAD(P)H oxidase inhibitor apocynin also prevented the ADMA-induced increase in P alb . The NO-independent soluble guanylyl cyclase (sGC) activator BAY 41-2272, at concentrations that increased glomerular cGMP production, attenuated the ADMA-induced increase in P alb . Furthermore, sGC incapacitation by the heme site-selective inhibitor ODQ increased P alb . We conclude that ADMA compromises the integrity of the filtration barrier by altering the bioavailability of NO and O 2 •- and that NO-independent activation of sGC preserves the integrity of this barrier under conditions of NO depletion. NO-independent activation of sGS may be a useful pharmacotherapeutic approach for preservation of glomerular function in CKD thereby reducing the risk for cardiovascular events.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Renal Physiology
Volume296
Issue number6
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

Glomerular Filtration Barrier
Superoxides
Nitric Oxide
omega-N-Methylarginine
Chronic Renal Insufficiency
Arginine
N,N-dimethylarginine
Nitric Oxide Donors
NADPH Oxidase
Heme
Nitric Oxide Synthase
Biological Availability
Albumins
Permeability

Keywords

  • Cardiorenal disease
  • Chronic kidney disease

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

ADMA injures the glomerular filtration barrier : Role of nitric oxide and superoxide. / Sharma, Mukut; Zhou, Zongmin; Miura, Hiroto; Papapetropoulos, Andreas; McCarthy, Ellen T.; Sharma, Ram; Savin, Virginia J.; Lianos, Elias A.

In: American Journal of Physiology - Renal Physiology, Vol. 296, No. 6, 01.06.2009.

Research output: Contribution to journalArticle

Sharma, Mukut ; Zhou, Zongmin ; Miura, Hiroto ; Papapetropoulos, Andreas ; McCarthy, Ellen T. ; Sharma, Ram ; Savin, Virginia J. ; Lianos, Elias A. / ADMA injures the glomerular filtration barrier : Role of nitric oxide and superoxide. In: American Journal of Physiology - Renal Physiology. 2009 ; Vol. 296, No. 6.
@article{8fc62f34057344408dee43e6034a8aec,
title = "ADMA injures the glomerular filtration barrier: Role of nitric oxide and superoxide",
abstract = "Chronic kidney disease (CKD) is associated with decreased renal nitric oxide (NO) production and increased plasma levels of methylarginines. The naturally occurring guanidino-methylated arginines N-monomethyl-L-arginine (L-NMMA) and asymmetric dimethyl-L-arginine (ADMA) inhibit NO synthase activity. We hypothesized that ADMA and L-NMMA compromise the integrity of the glomerular filtration barrier via NO depletion. We studied the effect of ADMA on albumin permeability (P alb ) in isolated glomeruli and examined whether this effect involves NO- and superoxide (O 2 •- )-dependent mechanisms. ADMA at concentrations found in circulation of patients with CKD decreased cGMP and increased P alb in a dose-dependent manner. A similar increase in P alb was caused by L-NMMA but at a concentration two orders of magnitude higher than that of ADMA. NO donor DETA-NONOate or cGMP analog abrogated the effect of ADMA on P alb . The SOD mimetic tempol or the NAD(P)H oxidase inhibitor apocynin also prevented the ADMA-induced increase in P alb . The NO-independent soluble guanylyl cyclase (sGC) activator BAY 41-2272, at concentrations that increased glomerular cGMP production, attenuated the ADMA-induced increase in P alb . Furthermore, sGC incapacitation by the heme site-selective inhibitor ODQ increased P alb . We conclude that ADMA compromises the integrity of the filtration barrier by altering the bioavailability of NO and O 2 •- and that NO-independent activation of sGC preserves the integrity of this barrier under conditions of NO depletion. NO-independent activation of sGS may be a useful pharmacotherapeutic approach for preservation of glomerular function in CKD thereby reducing the risk for cardiovascular events.",
keywords = "Cardiorenal disease, Chronic kidney disease",
author = "Mukut Sharma and Zongmin Zhou and Hiroto Miura and Andreas Papapetropoulos and McCarthy, {Ellen T.} and Ram Sharma and Savin, {Virginia J.} and Lianos, {Elias A.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1152/ajprenal.90369.2008",
language = "English (US)",
volume = "296",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - ADMA injures the glomerular filtration barrier

T2 - Role of nitric oxide and superoxide

AU - Sharma, Mukut

AU - Zhou, Zongmin

AU - Miura, Hiroto

AU - Papapetropoulos, Andreas

AU - McCarthy, Ellen T.

AU - Sharma, Ram

AU - Savin, Virginia J.

AU - Lianos, Elias A.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Chronic kidney disease (CKD) is associated with decreased renal nitric oxide (NO) production and increased plasma levels of methylarginines. The naturally occurring guanidino-methylated arginines N-monomethyl-L-arginine (L-NMMA) and asymmetric dimethyl-L-arginine (ADMA) inhibit NO synthase activity. We hypothesized that ADMA and L-NMMA compromise the integrity of the glomerular filtration barrier via NO depletion. We studied the effect of ADMA on albumin permeability (P alb ) in isolated glomeruli and examined whether this effect involves NO- and superoxide (O 2 •- )-dependent mechanisms. ADMA at concentrations found in circulation of patients with CKD decreased cGMP and increased P alb in a dose-dependent manner. A similar increase in P alb was caused by L-NMMA but at a concentration two orders of magnitude higher than that of ADMA. NO donor DETA-NONOate or cGMP analog abrogated the effect of ADMA on P alb . The SOD mimetic tempol or the NAD(P)H oxidase inhibitor apocynin also prevented the ADMA-induced increase in P alb . The NO-independent soluble guanylyl cyclase (sGC) activator BAY 41-2272, at concentrations that increased glomerular cGMP production, attenuated the ADMA-induced increase in P alb . Furthermore, sGC incapacitation by the heme site-selective inhibitor ODQ increased P alb . We conclude that ADMA compromises the integrity of the filtration barrier by altering the bioavailability of NO and O 2 •- and that NO-independent activation of sGC preserves the integrity of this barrier under conditions of NO depletion. NO-independent activation of sGS may be a useful pharmacotherapeutic approach for preservation of glomerular function in CKD thereby reducing the risk for cardiovascular events.

AB - Chronic kidney disease (CKD) is associated with decreased renal nitric oxide (NO) production and increased plasma levels of methylarginines. The naturally occurring guanidino-methylated arginines N-monomethyl-L-arginine (L-NMMA) and asymmetric dimethyl-L-arginine (ADMA) inhibit NO synthase activity. We hypothesized that ADMA and L-NMMA compromise the integrity of the glomerular filtration barrier via NO depletion. We studied the effect of ADMA on albumin permeability (P alb ) in isolated glomeruli and examined whether this effect involves NO- and superoxide (O 2 •- )-dependent mechanisms. ADMA at concentrations found in circulation of patients with CKD decreased cGMP and increased P alb in a dose-dependent manner. A similar increase in P alb was caused by L-NMMA but at a concentration two orders of magnitude higher than that of ADMA. NO donor DETA-NONOate or cGMP analog abrogated the effect of ADMA on P alb . The SOD mimetic tempol or the NAD(P)H oxidase inhibitor apocynin also prevented the ADMA-induced increase in P alb . The NO-independent soluble guanylyl cyclase (sGC) activator BAY 41-2272, at concentrations that increased glomerular cGMP production, attenuated the ADMA-induced increase in P alb . Furthermore, sGC incapacitation by the heme site-selective inhibitor ODQ increased P alb . We conclude that ADMA compromises the integrity of the filtration barrier by altering the bioavailability of NO and O 2 •- and that NO-independent activation of sGC preserves the integrity of this barrier under conditions of NO depletion. NO-independent activation of sGS may be a useful pharmacotherapeutic approach for preservation of glomerular function in CKD thereby reducing the risk for cardiovascular events.

KW - Cardiorenal disease

KW - Chronic kidney disease

UR - http://www.scopus.com/inward/record.url?scp=66449130085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66449130085&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.90369.2008

DO - 10.1152/ajprenal.90369.2008

M3 - Article

VL - 296

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 6

ER -